Paxlovid not linked to COVID-19 rebound, FDA says ahead of meeting to consider drug’s full approval
As the US Food and Drug Administration’s independent advisers prepare to discuss Thursday the full approval of Pfizer’s COVID-19 antiviral, Paxlovid,…
Continue Reading